Kaijia Tu

Kaijia Tu

Auto-generated profile, based on publicly available information

Kaijia Tu

Department of Oncology, Jiangxi Maternal and Child Health Hospital, No. 508 Xizhan Street, Nanchang, Jiangxi, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2023 in Experimental Cell Research
Verified
Journal Article
Closed access
MLMingmei Li
Mingmei Li
LLLi Li
Li Li
XCXiaoxiao Cheng
Xiaoxiao Cheng
LLLongyu Li
Longyu Li
KTKaijia Tu
Kaijia Tu

26 December 2021 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
YLYuFen Lu
YuFen Lu
YCYu Chen
Yu Chen
ZZZiYu Zhang
ZiYu Zhang
MLMingMei Li
MingMei Li
XCXiaoXiao Chen
XiaoXiao Chen
LLLongYu Li
LongYu Li

7 June 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
PQPing Qiu
Ping Qiu
YJYoukun Jie
Youkun Jie
CMCheng Ma
Cheng Ma
HCHuifeng Chen
Huifeng Chen
YQYunna Qin
Yunna Qin
ZZZiyu Zhang
Ziyu Zhang
As a molecular marker of the female reproductive system, Paired Box 8 is widely used in pathological diagnosis of gynecological tumors, but it is not clear whether its expression level is related to the development of uterine corpus endometrial carcinoma and molecular subtype classifications. Here, we show that PAX8 is up-regulated in TP53 mutation category of UCEC, which is result from the low methylation level of PAX8 in UCEC. We have identified that genes connected to ribosome, lysosome, ribosome biogenesis and cell cycle as PAX8 targets and demonstrate that modulation of the PAX8-DDX5 interaction influences c-MYC related cell cycle and cell growth. Our work defines DDX5 as a critical PAX8 co-factor, places the PAX8-DDX5 interaction in biological context, and highlights PAX8 as a key point for development of novel anti-MYC therapies in TP53-mutation UCEC.